首页> 外文期刊>Transplantation Proceedings >Late-Onset De Novo Minimal Change Disease Presenting With Nephrotic Range Proteinuria More Than 1 Year After Combined Heart-Kidney Transplant: A Case Report
【24h】

Late-Onset De Novo Minimal Change Disease Presenting With Nephrotic Range Proteinuria More Than 1 Year After Combined Heart-Kidney Transplant: A Case Report

机译:晚上缺课患有肾病射程蛋白尿的最小变化疾病超过1年患者肾脏移植术后1年:案例报告

获取原文
获取原文并翻译 | 示例
           

摘要

We present a case of de novo minimal change disease occurring more than 1 year after transplant in a combined heart-kidney transplant recipient. A 68-year-old white man with past medical history of nonischemic cardiomyopathy with left-ventricular assist device and end-stage renal disease due to type 2 diabetes mellitus and cardiorenal syndrome underwent a combined heart-kidney transplant in a sequential manner in August 2016. He was induced with rabbit antithymocyte globulin and methylprednisolone; he was maintained on mycophenolate mofetil, tacrolimus, and a protocolized tapering dose of prednisone. More than 1 year after transplant, in December 2017, he had about 2.3 g of proteinuria. Kidney function remained stable with a creatinine of 1.2 mg/dL. Serologic and infectious workup was nonrevealing. Proteinuria peaked at 4.5 g in January 2018, and kidney biopsy results were consistent with minimal change disease. After the biopsy, his prednisone dosage was escalated to 80.0 mg daily and slowly tapered to 2.5 mg (including most recent follow-up data from May 2019) daily, in alignment with improvement in his proteinuria and creatinine. Proteinuria decreased to 130.0 mg/g. To our knowledge, this is the first reported case of its kind in a combined heart-kidney transplant patient.
机译:我们提出了在组合的心脏肾移植受体中移植后超过1年的De Novo最小变化疾病的情况。一名68岁的白人与左心室辅助装置和左心室辅助装置和末期肾病的68岁的白人因2型糖尿病和心肺综合征,在2016年8月以顺序方式进行了组合的心肾移植。他用兔antithymocyte球蛋白和甲基己酮苷诱导;他维持在霉酚属Mofetil,Tacrolimus和倾向逐渐减少剂量的泼尼松剂量。移植后超过1年,2017年12月,他有大约2.3克蛋白尿。肾功能仍然稳定,肌酐为1.2 mg / dL。血清术和传染性掉期是不可掠夺的。 2018年1月在4.5克达到4.5克的蛋白尿,肾脏活检结果与最小的变化疾病一致。在活组织检查之后,他的泼尼松剂量每天升级至80.0mg并缓慢逐渐变为2.5毫克(包括来自2019年5月的最近后续数据),与他的蛋白尿和肌酐的改善相一致。蛋白尿下降至130.0mg / g。为了我们的知识,这是第一个在联合的心脏肾移植患者中进行的第一个报告的案例。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号